

Special Issue

Brain Metabolomics: New Perspective on Neurodegenerative Disorders

Message from the Guest Editor

Dear colleagues, This Special Issue broadly discusses protein clearance mechanisms via autophagy, the proteasome, and the lysosome in neurodegenerative diseases. It also will consider the direct effects on angiogenesis and the blood–brain barrier in health, disease and response to treatments. Inflammatory processes that are concurrent or independent of neurotoxic protein accumulation will also be considered. Papers concerning drug development as a strategy to treat neurodegeneration via manipulation of autophagy, the lysosome, and inflammation and restoration of the blood–brain barrier are particularly welcome.


Guest Editor

Dr. Charbel Moussa

Department of Neurology, Georgetown University Medical Center, Washington, DC, USA

Deadline for manuscript submissions

closed (30 June 2022)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/94407

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).